PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 11 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 2 years ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
BRIEF published on 05/28/2024 at 07:05, 2 years ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
PRESS RELEASE published on 05/28/2024 at 07:00, 2 years ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 2 years ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
BRIEF published on 05/23/2024 at 22:05, 2 years ago Results of the Combined General Meeting of Innate Pharma Voting Results Supervisory Board General Assembly Innate Pharma
PRESS RELEASE published on 05/23/2024 at 22:00, 2 years ago Informations privilégiées / Autres communiqués Innate Pharma annonce les résultats de l'Assemblée générale mixte du 23 mai 2024 avec réélection des membres du Conseil de Surveillance. Détails disponibles en ligne Résultats Conseil De Surveillance Assemblée Générale Mixte Innate Pharma Biotechnologies
PRESS RELEASE published on 05/23/2024 at 22:00, 2 years ago Inside Information / Other news releases Innate Pharma announces the voting results of its 2024 AGM. Quorum at 44.92%. Re-election of two Supervisory Board members. Details available on company's website Voting Results Supervisory Board Quorum 2024 AGM Innate Pharma
BRIEF published on 05/21/2024 at 07:05, 2 years ago Clarification sur le statut du traitement SAR443579 par Innate Pharma FDA Sanofi Innate Pharma SAR443579 Fast Track
BRIEF published on 05/21/2024 at 07:05, 2 years ago Clarification on the status of SAR443579 treatment by Innate Pharma FDA Sanofi Innate Pharma SAR443579 Fast Track
Published on 06/05/2026 at 02:55, 17 minutes ago Gold Basin Resources Announces Shareholder Approval of Arrangement With CANEX
Published on 06/05/2026 at 00:30, 2 hours 42 minutes ago American Critical Minerals Launches Early Warrant Exercise Incentive Program
Published on 06/05/2026 at 00:00, 3 hours 12 minutes ago Redwood AI Files Provisional Patent Application for Reactosphere Optimization Module Technology
Published on 06/04/2026 at 22:41, 4 hours 31 minutes ago UraniumX Announces Flow-Through Private Placement
Published on 06/04/2026 at 21:10, 6 hours 2 minutes ago Taranis Updates Shareholders on Disbursements of Taranis Securities to Matachewan and McChip Shareholders
Published on 06/04/2026 at 20:00, 7 hours 12 minutes ago Notes Reduction - Results of Consent Solicitation
Published on 06/04/2026 at 19:27, 7 hours 45 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/04/2026 at 18:30, 8 hours 42 minutes ago FROM DUPLANTIS TO PALTRINIERI, FAIR PLAY MENARINI KICKS OFF ITS 30TH EDITION
Published on 06/04/2026 at 17:57, 9 hours 15 minutes ago EQS-Adhoc: Viscom SE raises its forecast for incoming orders in the 2026 financial year following a major contract
Published on 06/04/2026 at 17:50, 9 hours 22 minutes ago Monport Laser Showcases Engraving Opportunities in Germany Ahead of World Cup 2026
Published on 06/04/2026 at 20:00, 7 hours 12 minutes ago Schneider Electric announces the reference share price the initial conversion/exchange ratio of its €850 million new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 and the results of the repurchase of the OC
Published on 06/04/2026 at 20:00, 7 hours 12 minutes ago Schneider Electric annonce le cours de référence le ratio initial de conversion/échange de son émission de 850 millions d’euros d’obligations à option de conversion et/ou d’échange en actions nouvelles et/ou existantes (OCEANEs) à échéance
Published on 06/04/2026 at 19:00, 8 hours 11 minutes ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 / Compte-rendu et résultats des votes des résolutions
Published on 06/04/2026 at 19:00, 8 hours 12 minutes ago ALTAREIT : Assemblée Générale Mixte du 4 juin 2026 / Compte-rendu et résultats des votes des résolutions
Published on 06/04/2026 at 18:23, 8 hours 49 minutes ago Assemblée générale et conseil d’administration du 4 juin 2026
